Literature DB >> 20109025

Domain III of the envelope protein as a dengue vaccine target.

Maria G Guzman1, Lisset Hermida, Lidice Bernardo, Rosa Ramirez, Gerardo Guillén.   

Abstract

A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109025     DOI: 10.1586/erv.09.139

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  38 in total

1.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

2.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Highly efficient selection of epitope specific antibody through competitive yeast display library sorting.

Authors:  Vinita Puri; Emily Streaker; Ponraj Prabakaran; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

4.  Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems.

Authors:  Johanna Gottschamel; Andreas Lössl; Stephanie Ruf; Yanliang Wang; Morten Skaugen; Ralph Bock; Jihong Liu Clarke
Journal:  Plant Mol Biol       Date:  2016-04-26       Impact factor: 4.076

5.  Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis.

Authors:  Guan-Ling Lin; Hsin-Hou Chang; Te-Sheng Lien; Po-Kong Chen; Hao Chan; Mei-Tzu Su; Chi-Yuan Liao; Der-Shan Sun
Journal:  Virulence       Date:  2017-07-20       Impact factor: 5.882

6.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

7.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

8.  Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes.

Authors:  David M Bowen; Jessica A Lewis; Wenzhe Lu; Catherine H Schein
Journal:  Vaccine       Date:  2012-07-31       Impact factor: 3.641

9.  Amino acid starvation enhances vaccine efficacy by augmenting neutralizing antibody production.

Authors:  Sumbul Afroz; Srikanth Battu; Shaikh Matin; Sabrina Solouki; Jessica P Elmore; Gillipsie Minhas; Weishan Huang; Avery August; Nooruddin Khan
Journal:  Sci Signal       Date:  2019-11-12       Impact factor: 8.192

10.  Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.

Authors:  Upasana Arora; Poornima Tyagi; Sathyamangalam Swaminathan; Navin Khanna
Journal:  J Nanobiotechnology       Date:  2012-07-13       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.